International Developed Markets — Revenues:
Pfizer International Developed Markets — Revenues: increased by 7.8% to $3.43B in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests successful product launches and strong demand in established global markets, while a decrease may indicate competitive pressure, patent expirations, or unfavorable currency fluctuations.
Detailed definition
This metric represents the total revenue generated from pharmaceutical product sales within established, high-income int...
Peer comparison
Peers in the pharmaceutical industry typically report similar geographic segments, often categorized as 'International' or 'Rest of World' developed markets, allowing for benchmarking of global commercial execution.
pfe_segment_international_developed_markets_revenuesHistorical Data
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $3.18B | $3.43B |
| QoQ Change | — | +7.8% |
| YoY Change | — | +7.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's international developed markets — revenues:?
- Pfizer (PFE) reported international developed markets — revenues: of $3.43B in Q1 2026.
- What does international developed markets — revenues: mean?
- Total revenue earned from pharmaceutical sales in mature, high-income international markets.